PainCast

Tag: nociceptive pain

  • Dorsal Root Ganglion Stimulation

    Dorsal Root Ganglion Stimulation

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on April 18, 2022

    Kenneth B. Chapman, MD – Director, Pain Medicine

    Dr. Kenneth Chapman presents an overview of current dorsal root ganglion stimulation (DRG-S) applications, outcomes, and future directions. Dr. Chapman explains the main differences between DRG-S and spinal cord stimulation (SCS). He mentions that among several distinctions, DRG-S is applied at subthreshold amplitudes that are imperceptible, while SCS is paresthesia-dependent. Dr. Chapman also mentions that DRG-S can facilitate pain neuromodulation by influencing the endogenous opioid system. He emphasizes additional benefits of DRG-S, including the management of joint nociceptive pain as demonstrated by a heightened quality of life, physical function, and mental health. Additionally, Dr. Chapman describes prospective DRG-S studies for low back pain.

    [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1488298613118{margin-top: -20px !important;}”]

    [/vc_column_text][/vc_column][/vc_row]

  • Molecular Biology of Pain

    Molecular Biology of Pain

    [vc_row css=”.vc_custom_1517939115140{padding-right: 20px !important;padding-left: 20px !important;background-color: #fbfbfb !important;}”][vc_column][vc_column_text]Published on November 24, 2020

    Dr. Nebojsa Nick Knezevic discusses innovative strategies to target the molecular mechanisms of pain. After reviewing nociceptive and neuropathic pain, inflammatory cytokines, and nociceptor diversity, he introduces pain-related voltage gated ion channels, glial and inflammatory cells, and G-protein-coupled receptor kinase 2 (GRK2). Dr. Knezevic provides compelling evidence that these are promising targets for pain treatment using strategies including monoclonal antibodies, biased μ-opioid receptor ligands, stem cells, and targeted gene therapy.

    [/vc_column_text][/vc_column][/vc_row]